Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05981131

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Non Muscle Invasive Bladder Cancer Clinical Trial

Official title:
QUILT-205: Long-Term Follow-Up of Subjects in QUILT-2.005 Phase 1b Trial of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Clinical Trial Summary

The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.

Clinical Trial Description

All 9 subjects that completed QUILT-2.005 phase 1b are planned to be enrolled in this study. Thus, the maximum enrollment for this study is 9 subjects. All enrolled subjects will be followed every 12 months for life, or until withdrawal of consent, or if the Sponsor closes the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05981131
Study type Observational
Source ImmunityBio, Inc.
Contact
Status Active, not recruiting
Phase
Start date August 17, 2023
Completion date August 30, 2033
View Details
See also
  Status Clinical Trial Phase
Completed NCT06020807 - Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
Recruiting NCT06167356 - Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Withdrawn NCT01799499 - A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) N/A
Completed NCT02343614 - Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05945108 - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Recruiting NCT06287541 - The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection N/A
Recruiting NCT06181266 - A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer Phase 1
Terminated NCT02982395 - Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Phase 3
Completed NCT06205277 - Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
Completed NCT01731652 - Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer Phase 2
Recruiting NCT03421236 - Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Phase 1
Active, not recruiting NCT04387461 - Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin Phase 2
Recruiting NCT06111235 - A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Phase 3
Recruiting NCT02895620 - Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC N/A
Completed NCT01004211 - Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging N/A